Paul Sirajuddin, Ph.D.
Affiliations: | 2013 | Tumor Biology | Georgetown University, Washington, DC |
Area:
Oncology, Cell Biology, BiochemistryGoogle:
"Paul Sirajuddin"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Chris Albanese | grad student | 2013 | Georgetown | |
| (Induction of apoptosis and autophagy by the small molecule inhibitor VMY-1-103 in cancer cell lines and reduction of tumor growth in vivo.) | ||||
Collaborators
Sign in to add collaborator| Michael S Moubarek | collaborator | 2012-2015 | Johns Hopkins Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Low JY, Sirajuddin P, Moubarek M, et al. (2019) Effective targeting of RNA polymerase I in treatment-resistant prostate cancer. The Prostate |
| Guner G, Sirajuddin P, Zheng Q, et al. (2017) Novel Assay to Detect RNA Polymerase I Activity in vivo. Molecular Cancer Research : McR |
| Guner G, Sirajuddin P, Zheng Q, et al. (2016) Abstract LB-186: Development and validation of a novel RNA in situ hybridization assay to detect RNA polymerase I activity in vivo Cancer Research. 76 |
| Ringer L, Sirajuddin P, Tricoli L, et al. (2014) The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget. 5: 10678-91 |
| Peltonen K, Colis L, Liu H, et al. (2014) Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. Molecular Cancer Therapeutics. 13: 2537-46 |
| Colis L, Ernst G, Sanders S, et al. (2014) Design, synthesis, and structure-activity relationships of pyridoquinazolinecarboxamides as RNA polymerase I inhibitors. Journal of Medicinal Chemistry. 57: 4950-61 |
| Sirajuddin P, Das S, Ringer L, et al. (2012) Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. Cell Cycle (Georgetown, Tex.). 11: 3801-9 |
| Sirajuddin P, Das S, Ringer L, et al. (2012) Abstract 4774: LC-MS/MS detection of the dansyl-modified biologically active CDK inhibitor VMY-1-103 using an in vivo model system Cancer Research. 72: 4774-4774 |
| Ringer L, Sirajuddin P, Yenugonda VM, et al. (2012) Abstract 3052: Role of p53 in cdk inhibitor VMY-1-103-induced apoptosis in prostate cancer Cancer Research. 72: 3052-3052 |
| Ringer L, Sirajuddin P, Heckler M, et al. (2011) VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biology & Therapy. 12: 818-26 |